CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Cannabidiol +1 moredrug
Likely dose
Cannabidiol 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02751359
NCT02751359Phase 2Completed
CompareCT.gov

Characterization of the Analgesic Effects of Oral CBD in Healthy, Normal Volunteers

University of California, Los Angeles·interventional·Posted Apr 26, 2016·Updated May 12, 2021

In Brief

A Phase 2 clinical trial evaluating Cannabidiol and Placebo for Pain. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this double-blind, placebo-controlled study is to determine the analgesic effects of cannabidiol (CBD), a chemical constituent found in cannabis that does not have intoxicating effects. The analgesic effects of CBD will be assessed using the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for the clinical use of analgesics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
CollaboratorsINSYS Therapeutics Inc

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 26, 2016
Enrollment StartJul 1, 2016
Primary CompletionJul 1, 2017
Study CompletionApr 1, 2020
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 10.2 years ago

Interventions

Cannabidioldrug

200, 400, or 800 mg Cannabidiol

Placebodrug

0 mg Cannabidiol